Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03811561 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
- 20
- Study locations
NCT03811561: Active Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.
NCT03811561 is a Phase 3 study of Diabetes Mellitus, Type 2 that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 1,500 participants, below the 4,481-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03811561, a Phase 3 study of Diabetes Mellitus, Type 2, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.
Primary Outcome
Percentage of subjects (yes/no).
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Placebo (semaglutide)
Study Locations (20)
California
- Southern California Res Ctr - Coronado
- FDRC - Costa Mesa
- Advanced Investigative Medicine, Inc. - Hawthorne
- Diabetes/Lipid Mgmt & Res Ctr - Huntington Beach
- Scripps Whittier Diabetes Inst - La Jolla
- Torrance Clin Res Inst, Inc. - Lomita
- Angel City Research, Inc. - Los Angeles
- Downtown LA Res Ctr. Inc. - Los Angeles
- Riverside University Health System Medical Center - Moreno Valley
- Rancho Cucamonga Clinical Research - Rancho Cucamonga
- Clinical Trials Research_Sacramento_0 - Sacramento
- UCLA Diabetes Center at Santa Monica - Santa Monica
- Coastal Metabolic Research Center - Ventura
- Diablo Clinical Research, Inc. - Walnut Creek
Arizona
- Synexus Rsch /Cnt Phnx Med C - Phoenix
- Del Sol Research Management, LLC - Tucson
- South Arizona VA Healthcare System - Tucson
- Synexus Cln Rsrch Inc - Orange Gro FP - Tucson
Colorado
- Barbara Davis Center - Aurora
- Rocky Mount Reg VA Med-DN - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2027-11-07 |
| Phase | Phase 3 |
What the registry record for NCT03811561 still lists
NCT03811561 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 4,481-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Semaglutide is the first listed.
NCT03811561 names 20 study sites across 3 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03811561 about?
NCT03811561 is a clinical study titled "A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes". This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - ...
What is the current status of trial NCT03811561?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2019-05-08. Estimated completion is 2027-11-07.
What conditions does trial NCT03811561 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT03811561?
The interventions under investigation include: Semaglutide (DRUG), Placebo (semaglutide) (DRUG).
Who is sponsoring clinical trial NCT03811561?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03811561 being conducted?
This trial has 20 study locations across Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03811561's enrollment target sits among peer trials
1,500 22nd of 348 higher than 327 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
-
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI